Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Depreciation and Depletion (2020 - 2023)

Historic Depreciation and Depletion for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q3 2023 value amounting to $404000.0.

  • Insight Molecular Diagnostics' Depreciation and Depletion rose 332.48% to $404000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.6 million, marking a year-over-year increase of 2424.47%. This contributed to the annual value of $1.5 million for FY2022, which is 8104.27% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Depreciation and Depletion stood at $404000.0 for Q3 2023, which was up 332.48% from $466000.0 recorded in Q4 2022.
  • Insight Molecular Diagnostics' Depreciation and Depletion's 5-year high stood at $466000.0 during Q4 2022, with a 5-year trough of -$216000.0 in Q4 2020.
  • Its 4-year average for Depreciation and Depletion is $212000.0, with a median of $255000.0 in 2021.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Depreciation and Depletion surged by 26956.52% in 2021 and then skyrocketed by 332.48% in 2023.
  • Quarter analysis of 4 years shows Insight Molecular Diagnostics' Depreciation and Depletion stood at -$216000.0 in 2020, then skyrocketed by 221.3% to $262000.0 in 2021, then surged by 77.86% to $466000.0 in 2022, then fell by 13.3% to $404000.0 in 2023.
  • Its Depreciation and Depletion was $404000.0 in Q3 2023, compared to $466000.0 in Q4 2022 and $391000.0 in Q3 2022.